Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and BioMed X have successfully applied a crowdsourcing approach to establish a research team of outstanding scientists from around the world with bright ideas, who will endeavor to identify new approaches for the treatment of patients with chronic obstructive pulmonary disease (COPD).
Bayer aligns organization with Life Science businesses
- Details
- Category: Bayer
Following the economic and legal separation of Covestro, Bayer is charting the course for its successful development as a Life Science company. On Friday, the Supervisory Board approved the reorganization proposed by the Board of Management. From January 1, 2016, the company’s business will be managed by three divisions: Pharmaceuticals, Consumer Health and Crop Science.
International survey shows quality of patient-physician conversation at diagnosis linked to better patient outcomes
- Details
- Category: Boehringer Ingelheim
New research shows that the quality of patient-physician communication at diagnosis of type 2 diabetes (T2D) may impact future patient self-care and well-being.(1) Data from the IntroDia™ Survey, the largest international survey of its kind, have quantitatively demonstrated this link using responses from more than 10,000 people with T2D across 26 countries.(1,2)
Amgen to acquire privately-held Dezima Pharma
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Dezima Pharma B.V. (Dezima) today announced that the companies have entered into a definitive acquisition agreement under which Amgen will acquire Dezima, a privately-held, Netherlands-based biotechnology company focused on developing innovative treatments for dyslipidemia. Dezima shareholders have approved the agreement.
Amgen and Xencor announce strategic collaboration in cancer immunotherapy and inflammation
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Xencor, Inc. (Xencor) (NASDAQ:XNCR) announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. The research collaboration brings together Amgen's capabilities in target discovery and protein therapeutics with Xencor's XmAb® bispecific technology platform.
New scholarships worth EUR 332,000 awarded by Bayer Foundation to promote international talents
- Details
- Category: Bayer
The Bayer Science & Education Foundation is making available approximately EUR 332,000 for 70 talented young people who wish to realize international study and vocational training projects. The new scholarship recipients are students of the natural sciences, agriculture and medicine, as well those training to become science teachers or young people from skilled non-academic professions.
Johnson & Johnson announces BARDA funding award to accelerate Ebola vaccine program
- Details
- Category: Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) announced today that Crucell Holland B.V., one of its Janssen Pharmaceutical Companies, has been awarded $28.5 million from The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, to help accelerate the development of its investigational Ebola prime-boost vaccine regimen.
More Pharma News ...
- For the 7th year running, Roche ranked most sustainable healthcare company in the Dow Jones Sustainability Indices
- Abbott named industry leader for responsible and sustainable business for three consecutive years on the Dow Jones Sustainability Index (DJSI)
- AstraZeneca purchases US biologics manufacturing facility to support growing pipeline
- Bristol-Myers Squibb Employees cycle nearly 2,900 miles to raise money for cancer research
- AstraZeneca to invest £11.5 million in new clinical oncology bioinformatics collaboration with The University of Manchester
- Novo Nordisk and MIT to collaborate on researching the next generation of drug delivery devices
- Novartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myeloma